Excerpts

When iwPSA was replaced by PSA, the odds ratio for PSA decreased (OR = 3.763, 95%CI 1.085–13.053, p = 0.037) and PSADT became marginally significant ( p = 0.058).

However, an increasing trend of IENF density was observed in the Fenofibrate 0.2%-Diet/PAC group in comparison to the Reg-diet/PAC group ( p = 0.058) ( Figure 3 ).

The association between elevated baseline LDH and shorter PFS on TT remained significant in the multivariate analysis adjusted for gender, age and stage (HR 1.12, 95% CI 1.00–1.27, p = 0.04), while it remained borderline significant for ICI (HR.1.42, 95% CI 0.99–2.05, p = 0.058).

The concentration of sPD-L1 in the plasma of EC patients was lower compared to the reference group; however, the observed difference narrowly missed statistical significance ( p = 0.0583) ( Figure 7 B).

The serum levels of sTREM2 were higher in advanced UICC stages, but they narrowly missed significance (SRC, p = 0.059).

Nevertheless, levels of sTREM2 were almost significantly correlated with UICC stages (SRC, p = 0.059).

The change in QUALMS-BF over time was borderline non-significant ( p = 0.059).

The association of perioperative transfusion and cancer recurrence after surgery for head and neck cancer was of borderline significance (adjusted HR = 1.4, 95% CI: 0.99~1.97, p = 0.059) after the adjustment for these significant predictors. 3.2.

There was close to significance of the rate of PD at the second radiological response evaluation ( p = 0.059).

Assuming that A is the risk allele, the dominant genetic model confirmed that carriers of the VEGFA −1190 A allele (A+AG) had a higher risk of death compared to homozygotes for the G allele univariately (HR = 1.79, 95% CI: 1.02–3.12, p = 0.042), while marginal significance was retained after adjustment for age, stage, and surgery (HR = 1.72, 95% CI: 0.98–3.03, p = 0.059, Table 3 ). 3.

Moreover, despite differences between patients who overexpressed and who underexpressed LYN were not statistically significant regarding CIR, they showed a trend toward significance (36.9 ± 11.6 vs. 44.9 ± 4.4%, p = 0.059) ( Figure 4 f,g).

Patients with involvement of fewer organs showed a trend towards better OS in patients with ≤2 vs. >2 organ involvement: median OS was 36 vs. 6 months (log-rank HR: 2.05; 95% CI: 0.75–5.56; p = 0.059), respectively.

Although post hoc comparisons did not reach statistical significance after Bonferroni correction, a clear trend toward higher TAN counts was observed in the c-erbB2-positive group compared with the c-erbB2-negative group (mean rank = 36.65 vs. 28.91, p = 0.059) ( Table 4 , Chart 4 ).

Additionally, 11OHA4 levels were higher in serous cases, though this difference was borderline significant ( p = 0.059) ( Supplementary Table S2 ).

Regarding the above mentioned differences between the two radiation dose groups ( Table 2 ), MVA revealed that the only significant factor that impacts LC is histology (N = 188; HR 2.234 95%-CI 1.399–3.566; p -value < 0.001; Table 3 ) with total radiation dose (>/<66 Gy) showing borderline significance ( p -value = 0.059).

Subsequently, a small phase III trial in Tunisia/France, studying 83 patients, used the same induction regimen and found a similar improvement in 3-year PFS (HR 0.44, 95% CI 0.20–0.97; p = 0.042) but a borderline significant 3-year OS (HR 0.40, 95% CI 0.15–1.04; p = 0.059) [ 17 ].

MYSEC-PM showed a trend toward inferior PFS in intermediate-2 and high groups than the favorable and intermediate-1 group ( p = 0.059), which is consistent with the results of previous studies.

Integrated models combining nodal status with PLR ± NLR improved risk discrimination: Model A (N + PLR ≥ 150 ± NLR ≥ 3) showed a trend ( p = 0.059), and Model B (N + PLR ≥ 150) reached significance ( p = 0.021; C-index ≈ 0.68–0.69).

At the end of the experiment (day 57), all mice receiving a single drug treatment had measurable tumors, and a similar tumor volume inhibition (TVI) (43%) was achieved in both groups barely approximating significance ( p = 0.059 trametinib, p = 0.053 pazopanib).

The comparison between both groups showed a trend towards better DC rate in the “matched therapy group” ( p = 5.9 × 10 −2 ).

Age, tumor location, and the 4-ARGs model were identified as significant independent prognostic factors, while TNM stage showed borderline significance ( p = 0.059, Figure 3 A).

However, when we performed the analysis with propensity-matched patients (150 matched patient pairs, Figure 3 b) we found a plausible improvement in PFS (HR = 0.719), with a trend towards significance ( p = 0.059).

Testing for the enrichment of proteins associated with either the non-canonical or the canonical WNT pathway revealed a significant ( p = 0.047) or nearly significant ( p = 0.059) overrepresentation, respectively.

In Cox regression analysis, there was a strong trend toward reduced mortality risk (HR = 0.4, 95% CI = 0.16–1.0; p = 0.0593). 3.3.3.

Several biomarkers demonstrated near-significant trends including IL-5 (OR 0.57, 95% CI: 0.22–1.02, p = 0.0597) and MDC (OR 0.49, 0.08–1.26, p = 0.144) but did not reach statistical significance. 4.